Genetic and Genomic Factors in Prostate Cancer for African American Men
Official title: Genetic and Genomic Variation in Prostate Cancer
Funded at Dana-Farber Cancer Inst · NIH-11535325 · Data updated 2026-11-12
This grant aims to understand how inherited genes and tumor genetics influence prostate cancer risk and aggressiveness in men, especially among African American populations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 7, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $39,355 |
| NIH project number | 3R01CA259200-05S2 |
| Project ID | NIH-11535325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with or at risk for prostate cancer, including individuals of African descent or African American ancestry.
✕Less likely to help
People without access to genetic testing or those not affected by prostate cancer may not directly benefit.
What this research studies
If funded, researchers will study how germline genetic variation and tumor DNA patterns relate to how often prostate cancer occurs and how it behaves in patients. The project will analyze genetic data and tumor characteristics to identify subtypes that may respond differently to treatment. By focusing on diverse genetic backgrounds, the work seeks to improve translation of genomic insights into personalized care for men with prostate cancer.
Why it matters
Potential benefit: Improved ability to predict risk and tailor treatments based on a patient’s genetic and tumor genomic profile.
How similar studies have gone: Previous work has shown that germline and somatic genomics influence prostate cancer, with growing evidence of actionable subtypes.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Rebbeck, Timothy Richard — Dana-Farber Cancer Inst
- Study coordinator: Rebbeck, Timothy Richard
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.